KAIST

KAIST (President Kwang-Hyung Lee) announced on the 10th of April that it successfully promoted the world’s first ‘Space Sound Source Transmission Project’ based on media art at the KAIST Space Research Institute on April 9th through collaboration between Professor Jinjoon Lee of the Graduate School of Culture Technology, a world-renowned media artist, and the global K-Pop artist, G-Dragon. This project was proposed as part of the ‘AI Entertech Research Center’ being promoted by KAIST and Galaxy Corporation. It is a project to transmit the message and sound of G-Dragon (real name, Kwon Ji-yong), a singer/song writer affiliated with Galaxy Corporation and a visiting professor in the Department of Mechanical Engineering at KAIST, to space for the first time in the world. This is a convergence project that combines science, technology, art, and popular music, and is a new form of ‘space culture content’ experiment that connects KAIST’s cutting-edge space technology, Professor Jinjoon Lee’s media art work, and G-Dragon’s voice and sound source containing his latest digital single, "HOME SWEET HOME". < Photo 1. Professor Jinjoon Lee's Open Your Eyes Project "Iris"'s imagery projected on the 13m space antenna at the Space Research Institute > This collaboration was planned with the theme of ‘emotional signals that expand the inner universe of humans to the outer universe.’ The image of G-Dragon’s iris was augmented through AI as a window into soul symbolizing his uniqueness and identity, and the new song “Home Sweet Home” was combined as an audio message containing the vibration of that emotion. This was actually transmitted into space using a next-generation small satellite developed by KAIST Space Research Institute, completing a symbolic performance in which an individual’s inner universe is transmitted to outer space. Professor Jinjoon Lee’s cinematic media art work “Iris” was unveiled at the site. This work was screened in the world’s first projection mapping method* on KAIST Space Research Institute’s 13m space antenna. This video was created using generative artificial intelligence (AI) technology based on the image of G-Dragon's iris, and combined with sound using the data of the sounds of Emile Bell rings – the bell that holds a thousand years of history, it presented an emotional art experience that transcends time and space. *Projection Mapping: A technology that projects light and images onto actual structures to create visual changes, and is a method of expression that artistically reinterprets space. This work is one of the major research achievements of KAIST TX Lab and Professor Lee based on new media technology based on biometric data such as iris, heartbeat, and brain waves. Professor Jinjoon Lee said, "The iris is a symbol that reflects inner emotions and identity, so much so that it is called the 'mirror of the soul,' and this work sought to express 'the infinite universe seen from the inside of humanity' through G-Dragon's gaze." < Photo 2. (From left) Professor Jinjoon Lee of the Graduate School of Culture Technology and G-Dragon (Visiting Professor Kwon Ji-yong of the Department of Mechanical Engineering) > He continued, "The universe is a realm of technology as well as a stage for imagination and emotion, and I look forward to an encounter with the unknown through a new attempt to speak of art in the language of science including AI and imagine science in the form of art." “G-Dragon’s voice and music have now begun their journey to space,” said Yong-ho Choi, Galaxy Corporation’s Chief Happiness Officer (CHO). “This project is an act of leaving music as a legacy for humanity, while also having an important meaning of attempting to communicate with space.” He added, “This is a pioneering step to introduce human culture to space, and it will remain as a monumental performance that opens a new chapter in the history of music comparable to the Beatles.” Galaxy Corporation is leading the future entertainment technology industry through its collaboration with KAIST, and was recently selected as the only entertainment technology company in a private meeting with Microsoft CEO Nadella. In particular, it is promoting the globalization of AI entertainment technology, receiving praise as a “pioneer of imagination” for new forms of AI entertainment content, including the AI contents for the deceased. < Photo 3. Photo of G-Dragon's Home Sweet Home being sent into the space via Professor Jinjoon Lee's Space Sound Source Transmission Project > Through this project, KAIST Space Research Institute presented new possibilities for utilizing satellite technology, and showed a model for science to connect with society in a more popular way. KAIST President Kwang-Hyung Lee said, “KAIST is a place that always supports new imaginations and challenges,” and added, “We will continue to strive to continue creative research that no one has ever thought of, like this project that combines science, technology, and art.” In the meantime, Galaxy Corporation, the agency of G-Dragon’s Professor Kwon Ji-yong, is an AI entertainment company that presents a new paradigm based on IP, media, tech, and entertainment convergence technology. 

Immune checkpoint inhibitors, a class of immunotherapies that help immune cells attack cancer more effectively, have revolutionized cancer treatment. However, fewer than 20% of patients respond to these treatments, highlighting the urgent need for new strategies tailored to both responders and non-responders. KAIST researchers have discovered that 'DEAD-box helicases 54 (DDX54)', a type of RNA-binding protein, is the master regulator that hinders the effectiveness of immunotherapy—opening a new path for lung cancer treatment. This breakthrough technology has been transferred to faculty startup BioRevert Inc., where it is currently being developed as a companion therapeutic and is expected to enter clinical trials by 2028. < Photo 1. (From left) Researcher Jungeun Lee, Professor Kwang-Hyun Cho and Postdoctoral Researcher Jeong-Ryeol Gong of the Department of Bio and Brain Engineering at KAIST > KAIST (represented by President Kwang-Hyung Lee) announced on April 8 that a research team led by Professor Kwang-Hyun Cho from the Department of Bio and Brain Engineering had identified DDX54 as a critical factor that determines the immune evasion capacity of lung cancer cells. They demonstrated that suppressing DDX54 enhances immune cell infiltration into tumors and significantly improves the efficacy of immunotherapy. Immunotherapy using anti-PD-1 or anti-PD-L1 antibodies is considered a powerful approach in cancer treatment. However, its low response rate limits the number of patients who actually benefit. To identify likely responders, tumor mutational burden (TMB) has recently been approved by the FDA as a key biomarker for immunotherapy. Cancers with high mutation rates are thought to be more responsive to immune checkpoint inhibitors. However, even tumors with high TMB can display an “immune-desert” phenotype—where immune cell infiltration is severely limited—resulting in poor treatment responses. < Figure 1. DDX54 was identified as the master regulator that induces resistance to immunotherapy by orchestrating suppression of immune cell infiltration through cancer tissues as lung cancer cells become immune-evasive > Professor Kwang-Hyun Cho's research team compared transcriptome and genome data of lung cancer patients with immune evasion capabilities through gene regulatory network analysis (A) and discovered DDX54, a master regulator that induces resistance to immunotherapy (B-F). This study is especially significant in that it successfully demonstrated that suppressing DDX54 in immune-desert lung tumors can overcome immunotherapy resistance and improve treatment outcomes. The team used transcriptomic and genomic data from immune-evasive lung cancer patients and employed systems biology techniques to infer gene regulatory networks. Through this analysis, they identified DDX54 as a central regulator in the immune evasion of lung cancer cells. In a syngeneic mouse model, the suppression of DDX54 led to significant increases in the infiltration of anti-cancer immune cells such as T cells and NK cells, and greatly improved the response to immunotherapy. Single-cell transcriptomic and spatial transcriptomic analyses further showed that combination therapy targeting DDX54 promoted the differentiation of T cells and memory T cells that suppress tumors, while reducing the infiltration of regulatory T cells and exhausted T cells that support tumor growth. < Figure 2. In the syngeneic mouse model made of lung cancer cells, it was confirmed that inhibiting DDX54 reversed the immune-evasion ability of cancer cells and enhanced the sensitivity to anti-PD-1 therapy > In a syngeneic mouse model made of lung cancer cells exhibiting immunotherapy resistance, the treatment applied after DDX54 inhibition resulted in statistically significant inhibition of lung cancer growth (B-D) and a significant increase in immune cell infiltration into the tumor tissue (E, F). The mechanism is believed to involve DDX54 suppression inactivating signaling pathways such as JAK-STAT, MYC, and NF-κB, thereby downregulating immune-evasive proteins CD38 and CD47. This also reduced the infiltration of circulating monocytes—which promote tumor development—and promoted the differentiation of M1 macrophages that play anti-tumor roles. Professor Kwang-Hyun Cho stated, “We have, for the first time, identified a master regulatory factor that enables immune evasion in lung cancer cells. By targeting this factor, we developed a new therapeutic strategy that can induce responsiveness to immunotherapy in previously resistant cancers.” He added, “The discovery of DDX54—hidden within the complex molecular networks of cancer cells—was made possible through the systematic integration of systems biology, combining IT and BT.” The study, led by Professor Kwang-Hyun Cho, was published in the Proceedings of the National Academy of Sciences of the United States of America (PNAS) on April 2, 2025, with Jeong-Ryeol Gong being the first author, Jungeun Lee, a co-first author, and Younghyun Han, a co-author of the article. < Figure 3. Single-cell transcriptome and spatial transcriptome analysis confirmed that knockdown of DDX54 increased immune cell infiltration into cancer tissues > In a syngeneic mouse model made of lung cancer cells that underwent immunotherapy in combination with DDX54 inhibition, single-cell transcriptome (H-L) and spatial transcriptome (A-G) analysis of immune cells infiltrating inside cancer tissues were performed. As a result, it was confirmed that anticancer immune cells such as T cells, B cells, and NK cells actively infiltrated the core of lung cancer tissues when DDX54 inhibition and immunotherapy were concurrently administered.  (Paper title: “DDX54 downregulation enhances anti-PD1 therapy in immune-desert lung tumors with high tumor mutational burden,” DOI:  https://doi.org/10.1073/pnas.2412310122) This work was supported by the Ministry of Science and ICT and the National Research Foundation of Korea through the Mid-Career Research Program and Basic Research Laboratory Program. < Figure 4. The identified master regulator DDX54 was confirmed to induce CD38 and CD47 expression through Jak-Stat3, MYC, and NF-κB activation. > DDX54 activates the Jak-Stat3, MYC, and NF-κB pathways in lung cancer cells to increase CD38 and CD47 expression (A-G). This creates a cancer microenvironment that contributes to cancer development (H) and ultimately induces immune anticancer treatment resistance. < Figure 5. It was confirmed that an immune-inflamed environment can be created by combining DDX54 inhibition and immune checkpoint inhibitor (ICI) therapy. > When DDX54 inhibition and ICI therapy are simultaneously administered, the cancer cell characteristics change, the immune evasion ability is restored, and the environment is transformed into an ‘immune-activated’ environment in which immune cells easily infiltrate cancer tissues. This strengthens the anticancer immune response, thereby increasing the sensitivity of immunotherapy even in lung cancer tissues that previously had low responsiveness to immunotherapy.

Vision is one of the most crucial human senses, yet over 300 million people worldwide are at risk of vision loss due to various retinal diseases. While recent advancements in retinal disease treatments have successfully slowed disease progression, no effective therapy has been developed to restore already lost vision—until now. KAIST researchers have successfully developed a novel drug to restore vision. < Photo 1. (From left) Ph.D. candidate Museong Kim, Professor Jin Woo Kim, and Dr. Eun Jung Lee of KAIST Department of Biological Sciences > KAIST (represented by President Kwang Hyung Lee) announced on the 30th of March that a research team led by Professor Jin Woo Kim from the Department of Biological Sciences has developed a treatment method that restores vision through retinal nerve regeneration. The research team successfully induced retinal regeneration and vision recovery in a disease-model mouse by administering a compound that blocks the PROX1 (prospero homeobox 1) protein, which suppresses retinal regeneration. Furthermore, the effect lasted for more than six months. This study marks the first successful induction of long-term neural regeneration in mammalian retinas, offering new hope to patients with degenerative retinal diseases who previously had no treatment options. As the global population continues to age, the number of retinal disease patients is steadily increasing. However, no treatments exist to restore damaged retinas and vision. The primary reason for this is the mammalian retina's inability to regenerate once damaged. Studies on cold-blooded animals, such as fish—known for their robust retinal regeneration—have shown that retinal injuries trigger Müller glia cells to dedifferentiate into retinal progenitor cells, which then generate new neurons. However, in mammals, this process is impaired, leading to permanent retinal damage. < Figure 1. Schematic diagram of the mechanism of retinal regeneration through inhibition of PROX1 migration. PROX1 protein secreted from retinal damaged retinal neurons transfers to Müllerglia and inhibits dedifferentiation into neural progenitor cells and neural regeneration. When PROX1 is captured outside the cells by an antibody against PROX1 and its transfer to Müllerglia is interfered, dedifferentiation of Müllerglia cells and retinal regeneration processes are resumed, restoring visual function. > Through this study, the research team identified the PROX1 protein as a key inhibitor of Müller glia dedifferentiation in mammals. PROX1 is a protein found in neurons of the retina, hippocampus, and spinal cord, where it suppresses neural stem cell proliferation and promotes differentiation into neurons. The researchers discovered that PROX1 accumulates in damaged mouse retinal Müller glia, but is absent in the highly regenerative Müller glia of fish. Furthermore, they demonstrated that the PROX1 found in Müller glia is not synthesized internally but rather taken up from surrounding neurons, which fail to degrade and instead secrete the protein. Based on this finding, the team developed a method to restore Müller glia’s regenerative ability by eliminating extracellular PROX1 before it reaches these cells. < Figure 2. Retinal regeneration and visual recovery in a retinitis pigmentosa model mouse through Anti-PROX1 gene therapy. After administration of adeno-associated virus expressing PROX1 neutralizing antibodies (AAV2-Anti-PROX1) to the eyes of RP1 retinitis pigmentosa model mice with vision loss, the photoreceptor cell layer of the retina is restored (A) and vision is restored (B). > This approach involves using an antibody that binds to PROX1, developed by Celliaz Inc., a biotech startup founded by Professor Jin Woo Kim’s research lab. When administered to disease-model mouse retinas, this antibody significantly promoted neural regeneration. Additionally, when delivered, the antibody gene to the retinas of retinitis pigmentosa disease model mice, it enabled sustained retinal regeneration and vision restoration for over six months. The retinal regeneration-inducing therapy is currently being developed by Celliaz Inc. for application in various degenerative retinal diseases that currently lack effective treatments. The company aims to begin clinical trials by 2028. This study was co-authored by Dr. Eun Jung Lee of Celliaz Inc. and Museong Kim, a Ph.D. candidate at KAIST, as joint first authors. The findings were published online on March 26 in the international journal Nature Communications. (Paper Title: Restoration of retinal regenerative potential of Müller glia by disrupting intercellular Prox1 transfer | DOI: 10.1038/s41467-025-58290-8) Dr. Eun Jung Lee stated, "We are about completing the optimization of the PROX1-neutralizing antibody (CLZ001) and move to preclinical studies before administering it to retinal disease patients. Our goal is to provide a solution for patients at risk of blindness who currently lack proper treatment options." This research was supported by research funds from Korean National Research Foundation (NRF) and the Korea Drug Development Foundation (KDDF).

In silico analysis of five industrial microorganisms identifies optimal strains and metabolic engineering strategies for producing 235 valuable chemicals Climate change and the depletion of fossil fuels have raised the global need for sustainable chemical production. In response to these environmental challenges, microbial cell factories are gaining attention as eco-friendly platforms for producing chemicals using renewable resources, while metabolic engineering technologies to enhance these cell factories are becoming crucial tools for maximizing production efficiency. However, difficulties in selecting suitable microbial strains and optimizing complex metabolic pathways continue to pose significant obstacles to practical industrial applications. KAIST (President Kwang-Hyung Lee) announced on 27th of March that Distinguished Professor Sang Yup Lee’s research team in the Department of Chemical and Biomolecular Engineering comprehensively evaluated the production capabilities of various industrial microbial cell factories using in silico simulations and, based on these findings, identified the most suitable microbial strains for producing specific chemicals as well as optimal metabolic engineering strategies. Previously, researchers attempted to determine the best strains and efficient metabolic engineering strategies among numerous microbial candidates through extensive biological experiments and meticulous verification processes. However, this approach required substantial time and costs. Recently, the introduction of genome-scale metabolic models (GEMs), which reconstruct the metabolic networks within an organism based on its entire genome information, has enabled systematic analysis of metabolic fluxes via computer simulations. This development offers a new way to overcome limitations of conventional experimental approaches, revolutionizing both strain selection and metabolic pathway design. Accordingly, Professor Lee’s team at the Department of Chemical and Biomolecular Engineering, KAIST, evaluated the production capabilities of five representative industrial microorganisms—Escherichia coli, Saccharomyces cerevisiae, Bacillus subtilis, Corynebacterium glutamicum, and Pseudomonas putida—for 235 bio-based chemicals. Using GEMs, the researchers calculated both the maximum theoretical yields and the maximum achievable yields under industrial conditions for each chemical, thereby establishing criteria to identify the most suitable strains for each target compound.   < Figure 1. Outline of the strategy for improving microbial cell factories using a genome-scale metabolic model (GEM) > The team specifically proposed strategies such as introducing heterologous enzyme reactions derived from other organisms and exchanging cofactors used by microbes to expand metabolic pathways. These strategies were shown to increase yields beyond the innate metabolic capacities of the microorganisms, resulting in higher production of industrially important chemicals such as mevalonic acid, propanol, fatty acids, and isoprenoids. Moreover, by applying a computational approach to analyze metabolic fluxes in silico, the researchers suggested strategies for improving microbial strains to maximize the production of various chemicals. They quantitatively identified the relationships between specific enzyme reactions and target chemical production, as well as the relationships between enzymes and metabolites, determining which enzyme reactions should be up- or down-regulated. Through this, the team presented strategies not only to achieve high theoretical yields but also to maximize actual production capacities.   < Figure 2. Comparison of production routes and maximum yields of useful chemicals using representative industrial microorganisms > Dr. Gi Bae Kim, the first author of this paper from the KAIST BioProcess Engineering Research Center, explained, “By introducing metabolic pathways derived from other organisms and exchanging cofactors, it is possible to design new microbial cell factories that surpass existing limitations. The strategies presented in this study will play a pivotal role in making microbial-based production processes more economical and efficient.” In addition, Distinguished Professor Sang Yup Lee noted, “This research serves as a key resource in the field of systems metabolic engineering, reducing difficulties in strain selection and pathway design, and enabling more efficient development of microbial cell factories. We expect it to greatly contribute to the future development of technologies for producing various eco-friendly chemicals, such as biofuels, bioplastics, and functional food materials.” This research was conducted with the support from the Development of platform technologies of microbial cell factories for the next-generation biorefineries project and Development of advanced synthetic biology source technologies for leading the biomanufacturing industry project (Project Leader: Distinguished Professor Sang Yup Lee, KAIST) from National Research Foundation supported by the Korean Ministry of Science and ICT.

Understanding biomolecular processes - such as protein-protein interactions and enzyme-substrate reactions that occur on the microseconds to millisecond time scale is essential for comprehending life processes and advancing drug development. KAIST researchers have developed a method for freezing and analyzing biochemical reaction dynamics within a span of just a few milliseconds, marking a significant step forward in better understanding complex biological reactions. < Photo. (From left) Professor Jin Young Kang and Haerang Hwang of the Integrated Master's and Doctoral Program of the Department of Chemistry, along with Professor Wonhee Lee of the Department of Physics > KAIST (represented by President Kwang Hyung Lee) announced on the 24th of March that a joint research team led by Professor Jin Young Kang from the Department of Chemistry and Professor Wonhee Lee from the Department of Physics has developed a parylene-based thin-film microfluidic mixing-and-spraying device for ultra-fast biochemical reaction studies. *Parylene: A key material for microfluidic devices used to observe protein dynamics at ultra-high speeds. It can be fabricated into a few micrometer-thick films, which can be used in making a spray nozzle for microfluidic devices. This research overcomes the limitations of the existing time-resolved cryo-electron microscopy (TRCEM) method by reducing sample consumption to one-third of the conventional amount while improving the minimum time resolution—down to just six milliseconds (6 ms). TRCEM is a technique that rapidly freezes protein complexes during intermediate reaction stages under cryogenic conditions, which allows researchers to analyze their structures. This approach has gained significant attention recently for its ability to capture transient biochemical events. < Figure 1. Time-resolved cryo-EM (TRCEM) technique using microfluidic channels. In order to capture the intermediate structure of biomolecules during a biochemical reaction over time, biomolecules and reaction substrates are mixed in a microfluidic channel, and then sprayed on a grid after a certain reaction time and frozen in liquid ethane to prepare a cryo-EM sample. This can then be analyzed by cryo-EM to observe the structural changes of proteins over time. > Transient intermediate structures of protein complexes could not be captured by traditional cryo-electron microscopy due to their extremely short lifespans. Although several TRCEM techniques have been developed to address this issue, previous methods were hindered by large sample consumption and limited time resolution. To overcome these challenges, the KAIST team developed a new mixing-and-spraying device using ultra-thin parylene films. The integrated design of the device further enhanced the precision and reproducibility of experiments. < Figure 2. TRCEM grid fabrication setup using a parylene-based thin-film microfluidic device and actual appearance of the device. You can see that a thin-film parylene channel is inserted into the injection nozzle. The integration of the reaction channel and the injection nozzle allowed the residence time in the device to be reduced to at least 0.5 ms. > “This research makes TRCEM more practical and paves the way for diverse applications of the parylene thin-film device in structural biology, drug development, enzyme reaction studies, and biosensor research.” Professor Jin Young Kang explained, emphasizing the significance of the study. Professor Wonhee Lee added, “The team aims to continue this research, focusing on improvement of the technique to achieve higher time resolution with minimal sample consumption.” < Figure 3. Comparison of the spraying patterns of the parylene mixing-jet device and the conventional mixing-jet device and the filament length in the resulting RecA-ssDNA filament formation reaction. It was shown that the thin film spray nozzle structure affects the uniformity and accuracy of the final reaction time. > The research findings, with Haerang Hwang (a graduate student in the integrated master's and Ph.D. program in the Department of Chemistry) as the first author, were published online on January 28, 2025, in the international journal Advanced Functional Materials. (Paper Title: “Integrated Parylene-Based Thin-Film Microfluidic Device for Time-Resolved Cryo-Electron Microscopy”, DOI: doi.org/10.1002/adfm.202418224) This research was supported by the National Research Foundation of Korea (NRF), the Samsung Future Technology Development Program, and the CELINE consortium.

KAIST (President Kwang-Hyung Lee) announced on the 9th that it will hold a signboard ceremony for the establishment of the ‘AI Entertech Research Center’ with the artificial intelligence entertech company, Galaxy Corporation (CEO Yong-ho Choi) at the main campus of KAIST. < (Galaxy Corporation, from center to the left) CEO Yongho Choi, Director Hyunjung Kim and related persons / (KAIST, from center to the right) Professor SeungSeob Lee of the Department of Mechanical Engineering, Provost and Executive Vice President Gyun Min Lee, Dean Jung Kim of the Department of Mechanical Engineering and Professor Yong Jin Yoon of the same department > This collaboration is a part of KAIST’s art convergence research strategy and is an extension of its efforts to lead future K-Culture through the development of creative cultural content based on science and technology. Beyond simple technological development, KAIST has been continuously implementing the convergence model of ‘Tech-Art’ that expands the horizon of the content industry through the fusion of emotional technology and cultural imagination. Previously, KAIST established the ‘Sumi Jo Performing Arts Research Center’ in collaboration with world-renowned soprano Sumi Jo, a visiting professor, and has been leading the convergence research of art and engineering, such as AI-based interactive performance technology and immersive content. The establishment of the ‘AI Entertech Research Center’ this time is being evaluated as a new challenge for the technological expansion of the K-content industry. In addition, the role of singer G-Dragon (real name Kwon Ji-yong), an artist affiliated with Galaxy Corporation and a visiting professor in the Department of Mechanical Engineering at KAIST, was also a major factor. Since being appointed to KAIST last year, Professor Kwon has been actively promoting the establishment of a research center and soliciting KAIST research projects through his agency to develop the ‘AI Entertech’ field, which fuses entertainment and cutting-edge technology. < (Galaxy Corporation, from center to the left) CEO Yongho Choi, Director Hyunjung Kim and related persons / (KAIST, from center to the right) Professor SeungSeob Lee of the Department of Mechanical Engineering, Provost and Executive Vice President Gyun Min Lee, Dean Jung Kim of the Department of Mechanical Engineering and Professor Yong Jin Yoon of the same department > The AI Entertech Research Center is scheduled to officially launch in the third quarter of this year, and this inauguration ceremony was held in line with Professor Kwon Ji-yong’s schedule to visit KAIST. Galaxy Corporation recently had a private meeting with Microsoft (MS) CEO Nadella as the only entertech company, and is actively promoting the globalization of AI entertech. In addition, since last year, it has established a cooperative relationship with KAIST and plans to actively seek the convergence of entertech and technology that transcends time and space through the establishment of a research center. Professor Kwon Ji-yong will attend the ‘Innovate Korea 2025’ event co-hosted by KAIST, Herald Media Group, and the National Research Council of Science and Technology, held at the KAIST Lyu Keun-Chul Sports Complex in the afternoon of the same day, and will give a special talk on the topic of ‘The Future of AI Entertech.’ In addition to Professor Kwon, Professor SeungSeob Lee of the Department of Mechanical Engineering at KAIST, Professor Sang-gyun Kim of Kyunghee University, and CEO Yong-ho Choi of Galaxy Corporation will also participate in this talk show. The two organizations signed an MOU last year to jointly research science and technology for the global spread of K-pop, and the establishment of this research center is the first tangible result of this. Once the research center is fully operational, various projects such as the development of an AI-based entertech platform and joint research on global content technology will be promoted. < A photo of Professor Kwon Ji-yong (right) from at the talk show with KAIST President Kwang-Hyung Lee (left) from the previous year > Yong-ho Choi, Galaxy Corporation CHO (Chief Happiness Officer), said, “This collaboration is the starting point for providing a completely new entertainment experience to fans around the world by grafting KAIST AI and cutting-edge technologies onto the fandom platform,” and added, “The convergence of AI and entertech is not just technological advancement; it is a driving force for innovation that enriches human life.” Kwang-Hyung Lee, KAIST President, said, “I am confident that KAIST’s scientific and technological capabilities, combined with Professor Kwon Ji-yong’s global sensibility, will lead the technological evolution of K-culture,” and added, “I hope that KAIST’s spirit of challenge and research DNA will create a new wave in the entertech market.” Meanwhile, Galaxy Corporation, the agency of Professor G-Dragon Kwon Ji-yong, is an AI entertainment technology company that presents a new paradigm based on IP, media, tech, and entertainment convergence technology. (End)

KAIST (President Kwang-Hyung Lee) announced on February 17th that it signed an agreement for cooperation in the bio-medical field with Formosa Group, one of the three largest companies in Taiwan. < Formosa Group Chairman Sandy Wang and KAIST President Kwang-Hyung Lee at the signing ceremony > Formosa Group Executive Committee member and Chairman Sandy Wang, who leads the group's bio and eco-friendly energy sectors, decided to establish a bio-medical research center within KAIST and invest approximately KRW 18 billion or more over 5 years. In addition, to commercialize the research results, KAIST and Formosa Group will establish a joint venture in Korea with KAIST Holdings, a KAIST-funded company. The cooperation between the two organizations began in early 2023 when KAIST signed a comprehensive exchange and cooperation agreement (MOU) with Ming Chi University of Science and Technology (明志科技大學), Chang Gung University (長庚大學), and Chang Gung Memorial Hospital (長庚記念醫院), which are established and supported by Formosa Group. Afterwards, Chairman Sandy Wang visited KAIST in May 2024 and signed a more specific business agreement (MOA). KAIST Holdings is a holding company established by KAIST, a government-funded organization, to attract investment and conduct business, and will pursue the establishment of a joint venture with a 50:50 equity structure in cooperation with Formosa Group. KAIST Holdings will invest KAIST’s intellectual property rights, and Formosa Group will invest a corresponding amount of funds. The KAIST-Formosa joint venture will provide research funds to the KAIST-Formosa Bio-Medical Research Center to be established in the future, secure the right to implement the intellectual property rights generated, and promote full-scale business. The KAIST-Formosa Bio-Medical Research Center will establish a ‘brain organoid bank’ created by obtaining tissues from hundreds of patients with degenerative brain diseases, thereby securing high-dimensional data that will reveal the fundamental causes of aging and disease. It is expected that KAIST’s world-class artificial intelligence technology will analyze large-scale patient data to find the causes of aging and disease. Through this business, it is expected that by 2030, five years from now, it will discover more than 10 types of intractable brain disease treatments and expand to more than 20 businesses, including human cell-centered diagnostics and preclinical businesses, and secure infrastructure and intellectual property rights that can create value worth approximately KRW 250 billion. The Chang Gung Memorial Hospital in Taiwan has 10,000 beds and handles 35,000 patients per day, and systematically accumulates patient tissue and clinical data. Chang Gung Memorial Hospital will differentiate the tissues of patients with degenerative brain diseases and send them to the KAIST-Formosa Bio-Medical Research Center, which will then produce brain organoids to be used for disease research and new drug development. This will allow the world’s largest patient tissue data bank to be established. Dean Daesoo Kim of the College of Life Science and Bioengineering at KAIST said, “This collaboration between KAIST and Formosa Group is a new research collaboration model that goes beyond joint research to establish a joint venture and global commercialization of developed technologies, and it is significant in that it can serve as an opportunity to promote biomedical research and development.” With this agreement, KAIST, which has been promoting the KAIST Advanced Regenerative Medicine Engineering Center in Osong K-Bio Square, has secured a practical global partner. < Representatives of the Formosa Group and KAIST > KAIST’s Senior Vice President for Planning and Budget, Professor Kyung-Soo Kim emphasized, “KAIST has made great efforts to secure an edge in state-of-the-art biomedical fields such as stem cells and gene editing technology, by attracting the world’s best experts and discovering global cooperation partners, and these results can ultimately be linked to the Osong K-Bio Square project.” SVP Kim then predicted, “In particular, the practical cooperation with Taiwan’s best Formosa Chang Gung Memorial Hospital, which has abundant clinical experience in stem cell treatment, will be an important axis of KAIST’s bio innovation strategy.” Formosa Chairman Sandy Wang emphasized that this investment and cooperation is built on trust in KAIST’s R&D capabilities and the passion of its researchers. And added that through this, the Formosa Group will practice corporate social responsibility and take an important first step together with KAIST to protect the welfare and health of humanity. She also went on the say that she expects to see the cooperation expanded to various fields such as mobility and semiconductors based on the successes begotten from the cooperation in the bio field. KAIST President Kwang-Hyung Lee said, “I evaluate this agreement as one of the most important events that will spearhead KAIST into overseas biotechnology stages,” and added, “I expect that this cooperation will be an opportunity for Taiwan and Korea, both of which have IT industry-centered structures, to create new growth engines in the bio industry.” Meanwhile, Formosa Group is a company founded by Chairman Sandy Wang’s father, Chairman Yung-Ching Wang. It is the world’s No. 1 plastic PVC producer and is leading core industries of the Taiwanese economy, including semiconductors, steel, heavy industry, bio, and batteries. Chairman Yung-Ching Wang was respected by the Taiwanese people for his exemplary return of wealth to society under the belief that the companies and assets he founded “belong to the people.”

KAIST (President Kwang-Hyung Lee) held its 2025 Commencement Ceremony at the Lyu Keun-Chul Sports Complex on the Daejeon Main Campus at 2 p.m. on the 14th of February. < A scene from KAIST Commencement 2025 - Guests of Honor and Administrative Professors Entering the Stage headed by the color guards of the ELKA (Encouraging Leaders of KAIST) > At this ceremony, a total of 3,144 degrees were conferred, including 785 doctorates, 1,643 masters, and 716 bachelors. With this, KAIST has produced a total of 81,156 advanced science and technology personnel, including 17,313 doctorates, 41,566 masters, and 22,277 bachelors since its establishment in 1971. Changyu Lee from the School of Computing received the Minister of Science and ICT Award, and the Chairman of the KAIST Board of Trustees Award went to Lance Khizner Dabu Gragasin, an international student from the Philippines of the Department of Chemical and Biological Engineering. The President’s Award was given to Seoyeong Yang of the Department of Biological Sciences, and the Alumni Association President’s Award and the Development Foundation Chairman’s Award was given to Gahyeon Bae of the Department of Industrial Design and Buyeon Kim of the Department of Mechanical Engineering, respectively. Minister of Science and ICT Sang-Im Yoo joined the ceremony to deliver a congratulatory speech and to present the awards to outstanding graduates. < Minister Sang-Im Yoo of the Ministry of Science, Technology and ICT giving his congratulatory message at KAIST Commencement 2025 > The valedictorian speeches were given by Minjae Kim of the School of Computing, who has practiced the value of sharing that learning is not competition but cooperation, and Mohammed Haruna Hamza of the Department of Aerospace Engineering, a Nigerian international student. Mr. Hamza is the first foreign student to represent the graduating class as valedictorian since the founding of KAIST. Hamza lost his home and school in his home country due to a terrorist group’s bombing and moved south, but despite the adversity, he continued his studies while pursuing his dream of becoming an aerospace engineer. As a result of his efforts, Hamza was invited by the Korean government to study at KAIST. He expressed his determination to pursue his dream by saying, “I am grateful for the people and experiences that helped me overcome my adversity. The future is the result of the decisions we make today.” A Pakistani international student was chosen as one of this year's "Most Talked about Graduates of the Year". It is Ali Syed Sheraz who wore his doctoral cap at this year’s commencement ceremony. Ali, a single father who left his one-year-old son behind in his home country, working as a university lecturer. He joined the Ph.D. program in mechanical engineering in 2019 with a passion for mechanical energy. Ali’s academic journey was full of challenges and growth. Due to COVID-19, his research was suspended for six months, and he had difficulty continuing his studies undergoing three surgeries after a bicycle accident, including a surgery for a fractured elbow, a nose surgery, and removal of kidney stones. However, he accepted these failure and hardship as a process of growth and participated in the ‘Failed Project Showcase’ and ‘Failure Essay Contest’ held by the KAIST Failure Society, sharing his experiences and growing into a more solid researcher. < Most Talked about Graduate Graduate of the Year - Syed Sheraz Ali > Despite experiencing various hardships, he found lessons to learn from them and changed his perspective, which made him unafraid of taking on new challenges. He showed through his own example that failure is not just stumbling blocks but can be a stepping stone to success by looking at his studies and personal life positively. Furthermore, after becoming the president of the Muslim Student Association, Ali introduced halal menus to the cafeteria on campus so that more Muslim students could eat comfortably. Thanks to this change, his time at KAIST has become an opportunity to understand and experience various cultures more. Ali is researching artificial muscles (soft actuators) with the world's highest bending strain using MXene, an artificial muscle nanomaterial that can move smoothly, in Professor Il-kwon Oh's lab. Ali said, "After completing my Ph.D., I plan to develop soft robots, healthcare electronics, and next-generation tactile technology based on MXene, a next-generation 2D material. It is important for my juniors not to be afraid of failure and to have a challenging attitude." Another 'Most Talked about Graduate of the Year', Mr. Sung-Hyun Jung, who graduated with a master's degree from the Graduate School of Bio Innvation Management, is the CEO of Promedius, a medical AI startup, and has commercialized an osteoporosis diagnosis software based on chest X-rays using AI, and grown it into a leading company in the bone health field. CEO Jung's challenge shows that KAIST's management education is not just theoretical but practical enough to be applied immediately in the field. CEO Jung, who is also the father of three daughters, experienced business failure in China during the period when the conflict between Korea and China was intensifying. He moved to Silicon Valley in the United States to revive his business and tried to acquire even small businesses, but the reality was not easy. He worked hard, standing 14 hours a day in a kimchi factory and a restaurant kitchen to make a living. After finishing his life in the United States, CEO Jung returned to Korea and had the opportunity to join Lunit, a global medical AI leader founded by KAIST graduates. CEO Jung experienced the growth of the global medical AI market firsthand with unit Chairman Seungwook Paek. When he entered the Master's Program at the Graduate School of Bio Innvation Management in 2023 to acquire more specialized knowledge, CEO Jung had just transferred to Promedius and was in a crisis situation with only about 6 months left before the company's funds were exhausted. While considering a change in business direction because he judged that it would be difficult to survive with existing business items, he learned keywords and investment review perspectives that venture capital (VC) pays attention to in Professor Hoonje Cho’s ‘Bio-innovation Business Startup Strategy and Practice’ class. He attracted 11.4 billion won in investment by applying the investment proposal he wrote based on what he learned from the class to actual practice.  < Most Talked about Graduate of the Year - Sung-Hyun Jung > In addition, he applied the innovation strategy in the medical field he learned in Professor Kihwan Park’s ‘Innovation and Marketing in Bio and Pharmaceutics’ to the field of osteoporosis, and achieved the result of being selected as the first Asian company to be a corporate advisory committee member of the International Osteoporosis Foundation (IOF). Through this, he established the company as a representative global entity in the osteoporosis field in just one year. CEO Jung, who applied what he learned from KAIST to actual management and achieved results in the global market in a short period of time, said, “I want to prove that KAIST education is not limited to theory, but is very practical.” He said, “I want to let people know that my life, once full of hardship, got on the track toward success after encountering KAIST,” and expressed his ambition, saying, “My long-term goal is to create a world-class company that is recognized globally.” In addition, an honorary doctorate was awarded to Chairman Joong Keun Lee of Booyoung Group at the commencement ceremony.  Chairman Joong Keun Lee, who is an entrepreneur that led Booyoung Group, a leading general construction company, received the honorary doctorate in business administration, for leading the development of domestic housing welfare, education, and culture. KAIST Provost Gyunmin Lee said, “Chairman Joong Keun Lee spared no effort in providing dedicated support for the development of domestic science and technology and the cultivation of future talents. He is awarded the honorary doctorate in recognition of his social responsibility in various fields, including scholarships and support for educational facilities, as well as domestic and international education, culture, veterans affairs, and overseas support.” Since founding Booyoung Group in 1983, Chairman Lee has boldly entered the rental housing business, a field that large construction companies had avoided, and has played a significant role in improving the quality of life of ordinary citizens by supplying 230,000 households out of 383 complexes and approximately 300,000 households nationwide as rental housing, thereby contributing greatly to the stability of national housing. < Chairman Joong Keun Lee giving his acceptance speech for his honorary Doctorate > Chairman Joong Keun Lee, who has been offering hope for a sustainable future, said, “I am honored to receive an honorary doctorate from KAIST, and I hope that KAIST students will nurture their dreams and talents and grow into global talents who will contribute to national development.”  President Kwang-Hyung Lee said, “Chairman Joong Keun Lee has been carrying out various social contribution activities, and in particular, through supporting academic infrastructure, which is the core of national competitiveness, we can see his deep interest in and sense of responsibility for the development of science and technology in our country.” He added, “I am truly delighted to have him as a member of the KAIST family, and I congratulate him on behalf of all members, including our students.” President Kwang-Hyung Lee also delivered a message of encouragement at the ceremony to charge the graduates to, “Find and keep a dream of your own, be on the lookout for opportunities, don’t be afraid of making mistakes, and do not shy away from taking on challenging tasks.” He added, “Even if you fail, don’t give up. Keep on trying so that you will get to that stage of radiate your own light on the stages where anything is possible.” (End)

Photo 1. Photo of the KAIST Alumni of the Year Award Recipients (From left) UST President Lee-whan Kim, CEO Han Chung of iThree Systems Co., Ltd., CEO Dong Myung Kim of LG Energy Solution Co., Ltd., and Professor Hyun Myung of the School of Electrical Engineering at KAIST KAIST (President Kwang Hyung Lee) announced on Monday, the 13th of January that the Alumni Association (President Yun-Tae Lee) has selected its Alumni of the Year. This year’s honorees are: ▴ President Lee-whan Kim of the Korea National University of Science and Technology (UST), ▴ CEO Han Chung of i3 Systems, ▴ CEO Dong Myung Kim of LG Energy Solution, and ▴ Professor Hyun Myung of the School of Electrical Engineering at KAIST. The honorees were selected based on their achievements over the past year, and the award ceremony will be held at the 2025 KAIST Alumni Association New Year’s Gathering to be held at the L Tower in Seoul at 5 PM on Friday the 17th. The KAIST Alumni of the Year Award is an award presented by the Alumni Association to alumni who have contributed to the development of the country and the society or have brought honor to their alma mater through outstanding academic achievements and community service. Since its establishment in 1992, 126 recipients have been awarded. Lee-whan Kim (Master's graduate of Mechanical Engineering, 82), the President of the Korea National University of Science and Technology (UST), established a leading foundation for national science and technology policy and strategy, and played a leading role in innovating national science and technology capabilities through the advancement of the national research and development system and the advancement of science and technology personnel training. In particular, he played a pivotal role in the establishment of UST and the Korea Science Academy (KSA), and greatly contributed to establishing a foundation for the training and utilization of science and technology personnel. Han Chung (Master's graduate of Electrical Engineering, 91, with Ph.D. degree in 96), the CEO of i3 Systems, is a first-generation researcher in the field of domestic infrared detectors. He developed military detectors for over 30 years and founded i3 Systems, a specialized infrared detector company, in 1998. Currently, he supplies more than 80% of the infrared detectors used by the Korean military, and has also achieved export results to over 20 countries. Dong Myung Kim (Master's graduate of Materials Science and Engineering, 94, with Ph.D. degree in 98) the CEO of LG Energy Solution Co., Ltd. has led innovation in the battery field with his ceaseless exploration and challenging spirit, and is known as an authority in the secondary battery industry. He played a leading role in establishing K-Battery as a global leader, strengthened the country's future industrial competitiveness, and greatly contributed to the development of science and technology. Hyun Myung (Bachelor's graduate of Electrical Engineering, 92, with Master's degree in 94, and Ph.D. degree in 98) a Professor of Electrical Engineering, KAIST, won first place in the world at the Quadruped Robot Challenge (QRC) hosted by the IEEE’s International Conference on Robotics and Automation (ICRA) 2023 with the 'DreamWaQ' system, an AI walking technology based on deep reinforcement learning that utilizes non-video sensory technologies. He contributed to enhancing the competitiveness of the domestic robot industry by developing his own fully autonomous walking technology that recognizes the environment around the robot and finds the optimal path. Yun-Tae Lee, the 27th president of the KAIST Alumni Association, said, “KAIST alumni have been the driving force behind the growth of industries in all walks of life by continuously conducting research and development in the field of advanced science and technology for a long time,” and added, “I am very proud of the KAIST alumni award recipients who are leading science and technology on the world stage beyond Korea, and I sincerely thank them for their efforts and achievements.”

< Photo 1. (From left) KAIST Dean of the College of Natural Sciences Daesoo Kim, KAIST President Kwang Hyung Lee, AT&C Chairman Ki Tae Lee, AT&C CEO Jong-won Lee > KAIST (President Kwang Hyung Lee) announced on January 9th that it signed a memorandum of understanding for a comprehensive mutual cooperation with AT&C (CEO Jong-won Lee) at its Seoul Dogok Campus to expand research investment and industry-academia cooperation in preparation for the future cutting-edge digital bio era. Senile dementia is a rapidly increasing brain disease that affects 10% of the elderly population aged 65 and older, and approximately 38% of those aged 85 and older suffer from dementia. Alzheimer's disease is the most common dementia in the elderly and its prevalence has been increasing rapidly in the population of over 40 years of age. However, an effective treatment is yet to be found. The Korean government is investing a total of KRW 1.1 trillion in dementia R&D projects from 2020 to 2029, with the goal of reducing the rate of increase of dementia patients by 50%. Since it takes a lot of time and money to develop effective and affordable medicinal dementia treatments, it is urgent to work on the development of digital treatments for dementia that can be applied more quickly. AT&C, a digital healthcare company, has already received approval from the Ministry of Food and Drug Safety (MFDS) for its device for antidepressant treatment based on transcranial magnetic stimulation (TMS) using magnetic fields and is selling it domestically and internationally. In addition, it has developed the first Alzheimer's dementia treatment device in Korea and received MFDS approval for clinical trials. After passing phase 1 to evaluate safety and phase 2 to test efficacy on some patients, it is currently conducting phase 3 clinical trials to test efficacy on a larger group of patients. This dementia treatment device is equipped with a system that combines non-invasive electronic stimulations (TMS electromagnetic stimulator) and digital therapeutic prescription (cognitive learning programs) to provide precise, automated treatment by applying AI image analysis and robotics technology. Through this agreement, KAIST and AT&C have agreed to cooperate with each other in the development of innovative digital treatment equipment for brain diseases. Through research collaboration with KAIST, AT&C will be able to develop technology that can be widely applied to Parkinson's disease, stroke, mild cognitive impairment, sleep disorders, etc., and will develop portable equipment that can improve brain function and prevent dementia at home by utilizing KAIST's wearable technology. To this end, AT&C plans to establish a digital healthcare research center at KAIST by supporting research personnel and research expenses worth approximately 3 billion won with the goal of developing cutting-edge digital equipment within 3 years. The digital equipment market is expected to grow at a compounded annual growth rate of 22.1% from 2023 to 2033, reaching a market size of $1.9209 trillion by 2033. < Photo 2. (From left) Dean of the KAIST College of Natural Sciences Daesoo Kim, Professor Young-joon Lee, Professor Minee Choi of the KAIST Department of Brain and Cognitive Sciences, KAIST President Kwang Hyung Lee, Chairman Ki Tae Lee, CEO Jong-won Lee, and Headquarters Director Ki-yong Na of AT&C > CEO Jong-won Lee said, “AT&C is playing a leading role in the treatment of Alzheimer’s disease using TMS (transcranial magnetic stimulation) technology. Through this agreement with KAIST, we will do our best to create a new paradigm for brain disease treatment and become a platform company that can lead future medical devices and medical technology.” Former Samsung Electronics Vice Chairman Ki Tae Lee, a strong supporter of this R&D project, said, “Through this agreement with KAIST, we plan to prepare for a new future by combining the technologies AT&C has developed so far with KAIST’s innovative and differentiated technologies.” KAIST President Kwang Hyung Lee emphasized, “Through this collaboration, KAIST expects to build a world-class digital therapeutics infrastructure for treating brain diseases and contribute greatly to further strengthening Korea’s competitiveness in the biomedical field.” The signing ceremony was attended by KAIST President Kwang Hyung Lee, the Dean of KAIST College of Natural Sciences Daesoo Kim, AT&C CEO Lee Jong-won, and the current Chairman of AT&C, Ki Tae Lee, former Vice Chairman of Samsung Electronics.

Outbound Exchange Student from EPFL

International Graduate Students at KAIST | EP 11. The Philippines

International Graduate Students at KAIST | EP 10. Turkiye